COVID-19 vaccine manufacturing has begun at a risk, will be ready by year-end: Pfizer CEO

CEO of Pfizer has said that COVID-19 vaccine being developed by pharmaceutical giant might be rey by year-end. Albert Bourla said that key data from trial should be available by October and will be submitted to US Food and Drug ministration (FDA) for approval. Pfizer CEO also ded that company is alrey manufacturing coronavirus vaccine to be rey for supply if it receives approval.

Pfizer's COVID-19 vaccine 

In an interview with CBS News, Pfizer CEO Albert Bourla informed people that US pharmaceutical might be able to provide COVID-19 vaccine to Americans if things go well with trials and FDA approval. He also said that Pfizer has alrey manufactured hundreds of thousands of vaccine doses to be prepared if approval goes through. Talking about COVID-19 vaccine trial, Bourla said that y are aiming to recruit younger people for trial which is currently studying people from 18 to 85 years old. People with comorbidities, special conditions chronic health conditions and illnesses like HIV will also be recruited to expand scope of study, ded Pfizer CEO in his interview. 

Re | FDA Ousts Spokeswoman For Exaggerating Plasma rapy Benefits For COVID-19 Treatment

Re | 'COVID Vaccine May Be Rey By First Quarter Of Next Year': Health Min Harsh Vardhan

During interview, Bourla said that w that Pfizer is taking risk of manufacturing vaccine without approval, pharmaceutical company may have to take a financial hit in case vaccine fails. He also said that in case Pfizer COVID-19 vaccine turns out to be effective and safe, chances are that a large number of people will t have access to vaccine until second half of 2021. Speaking about his decision of developing vaccine without government funding, CEO said that he wanted to protect Pfizer scientists from politics and ensure that y are free to focus on scientific challenges. 

Re | Oxford Resumes COVID Vaccine Trials In UK After Safety Review; Serum Awaits DCGI d

Re | Trump Accuses FDA 'Deep State' Of Slowing Vaccine Development To Sabot His Re-election

COVID-19 Vaccine Update

Oxford University and Serum Institute of India's COVID-19 vaccine candidate being developed in collaboration with AstraZeneca pharmaceutical were halted after a volunteer developed an illness. On Saturday, Oxford University anunced that trials will be resumed while ding that with 18,000 test cases, some of volunteers are bound to get unwell. In India, vaccine trials haven't been resumed yet since Drug Controller General of India (DCGI) order Serum Institute of India to halt trials and recruitment of volunteers for trials. While on or hand, COVID-19 vaccine candidate of Bharat Biotech 'Covaxin' h successful animal trials. 

Re | 'Animal Trials Of COVID-19 Vaccine Candidate Covaxin Successful': Bharat Biotech

Re | DCGI Orders Serum Institute Of India To Suspend Recruitment For Oxford COVID-19 Vaccine Trials